Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BRIER CREEK INTEGRATED PAIN & SPINE PLLC

NPI: 1538352760 · RALEIGH, NC 27617 · Medical Specialty Clinic/Center · NPI assigned 08/21/2007

$12.88M
Total Medicaid Paid
197,619
Total Claims
170,487
Beneficiaries
14
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialHARDISON, DEMETRIUS (PRACTICE MGR.)
NPI Enumeration Date08/21/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 33,447 $2.06M
2019 29,178 $1.80M
2020 21,596 $1.66M
2021 24,601 $1.67M
2022 25,512 $1.62M
2023 27,043 $1.73M
2024 36,242 $2.34M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 26,204 22,821 $3.84M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 46,300 38,453 $2.85M
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 72,185 63,071 $2.49M
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 31,317 27,894 $1.54M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 12,733 10,276 $1.50M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 3,118 2,879 $280K
99205 Prolong outpt/office vis 1,961 1,718 $191K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2,923 2,570 $173K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 76 69 $7K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 111 108 $2K
J1040 Injection, methylprednisolone acetate, 80 mg 641 583 $2K
62323 15 12 $1K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 23 21 $172.68
J1030 Injection, methylprednisolone acetate, 40 mg 12 12 $29.89